Key facts
- It has raised $7.3M; the latest was Early Stage VC ($4.4M) in Apr 2025.
- Notable investors include SPRIN-D.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AATec Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for AATec Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AATec Medical
Developer of a multi-product platform designed for the treatment of inflammatory diseases and viral infections. The company's platform offers industrial production of high-yield recombinant alpha-1 antitrypsin (AAT) and validates the therapeutic concept in several preclinical models, enabling patients to get cured of respiratory diseases.
- Sector
- Healthcare
- HQ
- Planegg-Martinsried, Germany
- Founded
- 2021
- Employees
- 6
- Website
- aatec-medical.com/
- Ownership
- Privately Held (backing)
AATec Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AATec Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AATec Medical in its N-PORT filings yet. We sweep new filings monthly.